Skip to main content
. 2017 Apr 10;8(34):56185–56198. doi: 10.18632/oncotarget.17015

Figure 5. Combining trastuzumab with NAC supplementation reduces proliferation and activation of the molecular Pi3K/Akt signaling pathway in trastuzumab resistant tumors.

Figure 5

proliferation index Ki67 (left) and pAkt levels (right) for (A) JIMT1 (HER2+/MUC4+) and (B) SKBr3 (HER2+/MUC4-) tumors in dual-tumor-bearing mice randomized to the four treatment arms CS (Control+Saline; blue, n = 5), CT (Control+Trastuzumab; purple, n = 5), NS (NAC+Saline; green, n = 5) and NT (NAC+Trastuzumab; red n = 5). Data are shown as mean ± SEM expressed in % positive cells for Ki67 index values and IM scores for pAkt levels with ***p < 0.001.